問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Hematology & Oncology

Division of Infectious Disease

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間:2023-09-19

張文震Chang, Wen-Cheng
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

篩選

List

182Cases

2024-01-22 - 2027-05-27

Phase III

Active
A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
  • Condition/Disease

    Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  • Test Drug

    injection

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2020-09-22 - 2024-03-29

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-10-01 - 2027-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-09-15 - 2025-10-08

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-12-14 - 2026-09-18

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-11-01 - 2025-01-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2025-04-04 - 2029-12-07

Phase I/II

Not yet recruiting
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Phase
  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    LUTATHERA® (AAA601) NETSPOT® (AAA501)

Participate Sites
3Sites

Recruiting3Sites

2018-12-07 - 2024-12-31

Phase III

Completed
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
  • Condition/Disease

    Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects

  • Test Drug

    ACZ885 (canakinumab)

Participate Sites
6Sites

Terminated6Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

江起陸
Taipei Veterans General Hospital

Division of Thoracic Medicine

2014-01-14 - 2016-10-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites